|Home||» Products||» Veterinary Medicine||» BIOCLAN 300MG TABLETS|
Clindamycin inhibits bacterial protein synthesis atthe ribosomal (50s sub-unit) level.
Clindamycin hydrochloride is rapidly absorbed fromthe canine gastrointestinal tract following oral administration. Effective clindamycin antibacterial serumlevels are reached within 30 minutes following administration of thetherapeutic dose.
Therapeutic serum levels of clindamycin can bemaintained by oral administration of 5.5 mg/kg bodyweight every 12 hours or 11mg/kg bodyweight every 24 hours; peak serum concentrations are on averagereached 75 minutes after oral administration. The biological plasma half-life of clindamycin in the dog isapproximately 5 hours. No accumulationof bioactivity has been observed in dogs after several oral administrations.
Metabolism and Excretion:
Extensive research of the metabolism and excretionpattern of clindamycin shows that the parent molecule as well as bioactive andbio-inactive metabolites is excreted via the urine and faeces. Nearly all bioactivity in the serum followingoral administration is due to the parent molecule (clindamycin).
Clindamycin uncoated tablet are indicated for use indogs as follows:
For the treatment of infected wounds and abscesses,and infected mouth cavity and dental infections, caused by or associated withStaphylococcus spp, Streptococcus spp (except Streptococcus faecalis),Bacteroides spp, Fusobacterium necrophorum, and Clostridium perfringens. Tohelp provide antimicrobial cover during dental procedures.
For the treatment of superficial pyoderma associatedwith Staphylococcus intermedius.
For the treatment of osteomyelitis, caused byStaphylococcus aureus.
Before Clindamycin therapy is initiated, theinvolved pathogens should be identified and sensitivity to clindamycinestablished.